Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG OTCMKTS:CXRXF NASDAQ:IMVT NASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$39.66+2.7%$31.95$16.50▼$43.58$3.46BN/A47,381 shs4,733 shsCXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsIMVTImmunovant$18.18+2.0%$15.71$12.72▼$34.47$3.11B0.631.22 million shs381,929 shsMLTXMoonLake Immunotherapeutics$53.97+2.8%$43.94$31.42▼$58.26$3.44B1.27385,839 shs340,434 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+5.06%-7.76%+20.20%+106.30%+3,861,999,900.00%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%IMVTImmunovant+1.83%+3.01%+14.98%+17.56%-42.40%MLTXMoonLake Immunotherapeutics+5.74%+8.78%+22.42%+37.02%+4.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/ACXRXFADVANZ PHARMAN/AN/AN/AN/AN/AN/AN/AN/AIMVTImmunovant1.3711 of 5 stars3.40.00.00.02.21.70.0MLTXMoonLake Immunotherapeutics1.735 of 5 stars3.51.00.00.01.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/ACXRXFADVANZ PHARMA 0.00N/AN/AN/AIMVTImmunovant 2.82Moderate Buy$36.3099.72% UpsideMLTXMoonLake Immunotherapeutics 3.00Buy$74.5038.05% UpsideCurrent Analyst Ratings BreakdownLatest CXRXF, MLTX, AAPG, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.006/3/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.005/19/2025MLTXMoonLake ImmunotherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$61.005/13/2025MLTXMoonLake ImmunotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$78.00 ➝ $80.005/13/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/30/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$66.00 ➝ $66.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M3.52N/AN/A$0.48 per share82.63CXRXFADVANZ PHARMA$525.58M1.59N/AN/A$0.16 per share106.63IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$7.09 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/ACXRXFADVANZ PHARMA-$74.86MN/AN/A∞N/A-15.31%N/A-4.38%N/AIMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.30N/AN/AN/AN/A-30.81%-28.40%8/6/2025 (Estimated)Latest CXRXF, MLTX, AAPG, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.73N/AN/AN/AN/AN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/12/2025Q1 2025MLTXMoonLake Immunotherapeutics-$0.76-$0.63+$0.13-$0.63N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ACXRXFADVANZ PHARMAN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International3.241.261.26CXRXFADVANZ PHARMA257.042.391.61IMVTImmunovantN/A11.1611.16MLTXMoonLake Immunotherapeutics0.1821.1121.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ACXRXFADVANZ PHARMAN/AIMVTImmunovant47.08%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ACXRXFADVANZ PHARMAN/AIMVTImmunovant1.80%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.12 millionN/AN/ACXRXFADVANZ PHARMA42948.91 millionN/ANot OptionableIMVTImmunovant120171.07 million167.99 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.32 millionOptionableCXRXF, MLTX, AAPG, and IMVT HeadlinesRecent News About These CompaniesRice Hall James & Associates LLC Purchases 26,383 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)July 14 at 6:36 AM | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $74.50 Consensus PT from AnalystsJuly 9, 2025 | americanbankingnews.comAnalysts Set MoonLake Immunotherapeutics (NASDAQ:MLTX) Target Price at $74.50July 9, 2025 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 6, 2025 | marketbeat.comMoody Aldrich Partners LLC Makes New $2.16 Million Investment in MoonLake Immunotherapeutics (NASDAQ:MLTX)July 4, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 2.7% - Here's WhyJuly 3, 2025 | marketbeat.comMoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock NewsJune 9, 2025 | gurufocus.comMoonLake Immunotherapeutics is for sale? This sounds like a cry for helpJune 5, 2025 | statnews.comSMoonLake Immunotherapeutics Breaks Above 200-Day Moving Average - Bullish for MLTXJune 5, 2025 | nasdaq.comMLTX Stock Gains 18% as Merck Reportedly Eyes BuyoutJune 4, 2025 | zacks.comMoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma InterestJune 3, 2025 | seekingalpha.comConstellation and Meta, Merck, Snowflake: Trending TickersJune 3, 2025 | finance.yahoo.comMerck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech: FTJune 3, 2025 | fiercebiotech.comFMoonLake Immunotherapeutics Catapults On Rumored Merck TakeoverJune 3, 2025 | msn.comMerck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: ReportJune 3, 2025 | benzinga.comMerck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: ReportJune 3, 2025 | finance.yahoo.comMoonLake Immunotherapeutics stock surges on FT report of Merck buyout talksJune 2, 2025 | investing.comMerck held talks to buy biotech MoonLake for over $3 billion, FT reportsJune 2, 2025 | reuters.comH.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PTMay 29, 2025 | finance.yahoo.comH.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PTMay 27, 2025 | insidermonkey.comWolfe Research Upgrades MoonLake Immunotherapeutics (MLTX)May 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCXRXF, MLTX, AAPG, and IMVT Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$39.66 +1.04 (+2.69%) As of 01:38 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.ADVANZ PHARMA OTCMKTS:CXRXF$17.06 0.00 (0.00%) As of 06/10/2021ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.Immunovant NASDAQ:IMVT$18.18 +0.37 (+2.05%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.MoonLake Immunotherapeutics NASDAQ:MLTX$53.97 +1.45 (+2.76%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
